MyFinsight
Home
Blog
About
Net increase in cash
and cash...
-$16,064,242
(-63.65%↓ Y/Y)
Net proceeds from
issuance of debt
$4,322,500
(-77.53%↓ Y/Y)
Proceeds from issuance of
warrants
$1,054,908
(-50.95%↓ Y/Y)
Proceeds from issuance of
common stock from...
$97,231
Accounts payable
$2,743,615
(-2.45%↓ Y/Y)
Loss on retirement of
debt
-$2,660,781
Stock-based compensation
expense
$1,126,054
(-33.84%↓ Y/Y)
Accrued expenses
$370,496
(126.82%↑ Y/Y)
Amortization of debt discount
$265,549
(-80.85%↓ Y/Y)
Depreciation expense
$8,387
(-23.18%↓ Y/Y)
Finance lease
depreciation expense
$6,742
(-65.14%↓ Y/Y)
Net cash
(used)/provided by financing...
-$13,271,733
(-259.57%↓ Y/Y)
Net cash used in
operating activities
-$2,792,509
(84.60%↑ Y/Y)
Canceled cashflow
$5,474,639
Canceled cashflow
$7,181,624
Interest income
$125,405
Loan repayment
$17,738,889
(-4.86%↓ Y/Y)
Net loss
-$9,750,575
(45.60%↑ Y/Y)
Loan principal
payment
$1,000,000
(-76.00%↓ Y/Y)
Payments of finance lease
obligations
$7,483
(-74.94%↓ Y/Y)
Canceled cashflow
$125,405
Prepaid expenses and
other assets
$223,558
(-95.50%↓ Y/Y)
Total operating
expenses
$6,496,734
Interest expense
$3,379,246
Back
Back
Cash Flow
PDS Biotechnology Corp (PDSB)
PDS Biotechnology Corp (PDSB)
source: myfinsight.com